Inhibrx Biosciences Inc. (NASDAQ:INBX) is one of the best emerging technology stocks to invest in. On December 16, Inhibrx ...

Pfizer PFE expects a significant negative impact on revenues from the loss of exclusivity (“LOE”) of several of its key ...

Aktis Oncology filed for an initial public offering in the United States on Friday, as stock market listings from the biotech ...

Policy, precision medicine, and new ways of delivering therapeutics were popular topics in 2025 among readers of ...

The monotherapy trial suggested a confirmed overall-response rate of 46% and a disease-control rate of 93%. In combination with Keytruda, the confirmed overall-response rate was 71% and the ...

CG Oncology leads in NMIBC treatment with creto, strong efficacy data, and $2B+ revenue potential. Learn more about CGON ...

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage companies focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today outlined continued ...

Patients are often stabilised for years on somatostatin analogues; however, progression eventually necessitates ...

In this study, researchers sought to determine the impact of the FDA’s Accelerated Approval pathway among patients with solid tumors.

Coherus Oncology, Inc. is rated a Buy driven by a promising clinical pipeline and undervaluation. Learn more about CHRS stock ...

Reliance Foundation Hospital inaugurates JEEVAN, a new oncology and dialysis wing dedicated to compassionate, patient-centric ...

Pamela Jones, DVM, DACVIM (Oncology), explains why lymphoma isn’t one disease and how phenotyping, client goals, and teamwork ...